XBRAF:OTC-Xebra Brands Ltd (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 0.025

Change

0.00 (0.00)%

Market Cap

USD 2.51M

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Xebra Brands Ltd. engages in the cultivation, processing, manufacture, design, and delivery of cannabis products in Canada, Europe, and Mexico. It provides cannabis infused beverages, including seltzers, soft drinks, iced teas, lemonades, waters, and energy and sport drinks; and wellness products that include capsules, tinctures, topicals, and intimate oils for personal care. The company offers its products under the HighJack, MadCap, Vicious Citrus, Conquer, HolaHi, and HighCastle brands. Xebra Brands Ltd. was incorporated in 2019 and is headquartered in Vancouver, Canada.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-04 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
MKGAF MERCK Kommanditgesellschaft au..

N/A

USD 78.02B
MKKGY Merck KGaA ADR

-0.56 (-1.62%)

USD 78.02B
HLNCF Haleon plc

-0.19 (-3.52%)

USD 47.79B
TKPHF Takeda Pharmaceutical Co. Ltd.

N/A

USD 45.46B
TEVJF Teva Pharmaceutical Industries..

N/A

USD 20.17B
SDZXF Sandoz Group AG

N/A

USD 18.03B
SDZNY Sandoz Group AG

+0.52 (+1.27%)

USD 17.36B
HNSPF Hansoh Pharmaceutical Group Co..

N/A

USD 13.26B
SWOBY Swedish Orphan Biovitrum AB (p..

N/A

USD 11.16B
ESALF Eisai Co. Ltd

N/A

USD 10.86B

ETFs Containing XBRAF

XSI:CA iShares Short Term Strate.. 7.09 % 0.56 %

N/A

CAD 0.04B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 66.67% 83% B 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 66.67% 82% B 88% B+
Trailing 12 Months  
Capital Gain -21.88% 57% F 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.88% 56% F 35% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -30.05% N/A N/A 8% B-
Dividend Return -30.05% N/A N/A 8% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 80.30% N/A N/A 38% F
Risk Adjusted Return -37.41% N/A N/A 19% F
Market Capitalization 2.51M 47% F 26% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector